269 related articles for article (PubMed ID: 33599841)
1. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
2. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
[TBL] [Abstract][Full Text] [Related]
3. Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.
Geiger JL; Ku JA
Curr Treat Options Oncol; 2019 Feb; 20(3):20. PubMed ID: 30771020
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Rosenberg AJ; Vokes EE
Oncologist; 2021 Jan; 26(1):40-48. PubMed ID: 32864799
[TBL] [Abstract][Full Text] [Related]
5. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
Patel RR; Ludmir EB; Augustyn A; Zaorsky NG; Lehrer EJ; Ryali R; Trifiletti DM; Adeberg S; Amini A; Verma V
Oral Oncol; 2020 Apr; 103():104608. PubMed ID: 32163853
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
[TBL] [Abstract][Full Text] [Related]
7. De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease.
Stock GT; Bonadio RRCC; de Castro G
Curr Opin Oncol; 2018 May; 30(3):146-151. PubMed ID: 29474271
[TBL] [Abstract][Full Text] [Related]
8. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy.
Taku N; Wang L; Garden AS; Rosenthal DI; Gunn GB; Morrison WH; Fuller CD; Phan J; Reddy JP; Moreno AC; Spiotto MT; Chronowski G; Shah SJ; Mayo LL; Gross ND; Ferrarotto R; Zhu XR; Zhang X; Frank SJ
Curr Treat Options Oncol; 2021 Jun; 22(6):54. PubMed ID: 34086150
[TBL] [Abstract][Full Text] [Related]
9. Has the time come for de-escalation in the management of oropharyngeal carcinoma?
Durkova J; Boldis M; Kovacova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Dec; 163(4):293-301. PubMed ID: 31796941
[TBL] [Abstract][Full Text] [Related]
10. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
11. [De-escalation concepts for chemoradiotherapy of HPV-positive oropharyngeal carcinomas: pros and cons].
Rühle A; Nicolay NH
HNO; 2021 Apr; 69(4):278-284. PubMed ID: 33048200
[TBL] [Abstract][Full Text] [Related]
12. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.
Rischin D; King M; Kenny L; Porceddu S; Wratten C; Macann A; Jackson JE; Bressel M; Herschtal A; Fisher R; Fua T; Lin C; Liu C; Hughes BGM; McGrath M; McDowell L; Corry J
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):876-886. PubMed ID: 34098030
[TBL] [Abstract][Full Text] [Related]
13. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
14. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
15. Special Issue about Head and Neck Cancers: HPV Positive Cancers.
Economopoulou P; Kotsantis I; Psyrri A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403287
[TBL] [Abstract][Full Text] [Related]
16. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
17. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies.
Mehanna H; Rischin D; Wong SJ; Gregoire V; Ferris R; Waldron J; Le QT; Forster M; Gillison M; Laskar S; Tahara M; Psyrri A; Vermorken J; Porceddu S
J Clin Oncol; 2020 Aug; 38(22):2552-2557. PubMed ID: 32496903
[TBL] [Abstract][Full Text] [Related]
18. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
[TBL] [Abstract][Full Text] [Related]
19. Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs.
Ventz S; Trippa L; Schoenfeld JD
Clin Cancer Res; 2019 Dec; 25(24):7281-7286. PubMed ID: 31527164
[TBL] [Abstract][Full Text] [Related]
20. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma.
Fung N; Faraji F; Kang H; Fakhry C
Cancer Metastasis Rev; 2017 Sep; 36(3):449-461. PubMed ID: 28812214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
